Hypothermia therapy: neurological and cardiac benefits. [Review]

MedStar author(s):
Citation: Journal of the American College of Cardiology. 59(3):197-210, 2012 Jan 17.PMID: 22240124Institution: MedStar Heart & Vascular InstituteForm of publication: Journal ArticleMedline article type(s): Journal Article | ReviewSubject headings: *Heart Arrest/th [Therapy] | *Hypothermia, Induced/mt [Methods] | *Myocardial Infarction/th [Therapy] | Animals | Heart Arrest/ep [Epidemiology] | Heart Arrest/pp [Physiopathology] | Humans | Myocardial Infarction/ep [Epidemiology] | Myocardial Infarction/pp [Physiopathology] | Nervous System Diseases/ep [Epidemiology] | Nervous System Diseases/pc [Prevention & Control] | Nervous System Diseases/pp [Physiopathology] | Randomized Controlled Trials as Topic/mt [Methods] | Ventricular Fibrillation/ep [Epidemiology] | Ventricular Fibrillation/pp [Physiopathology] | Ventricular Fibrillation/th [Therapy]Local holdings: Available online from MWHC library: 1995 - present, Available in print through MWHC library:1999-2007ISSN:
  • 0735-1097
Name of journal: Journal of the American College of CardiologyAbstract: Due to its protective effect on the brain and the myocardium, hypothermia therapy (HT) has been extensively studied in cardiac arrest patients with coma as well as in patients presenting with acute myocardial infarction (MI). In the setting of cardiac arrest, randomized studies have shown that HT decreases mortality and improves neurological outcomes. Subsequent guidelines have therefore recommended cooling (32C to 34C) for 12 to 24 h in unconscious adult patients with spontaneous circulation after out-of-hospital cardiac arrest due to ventricular fibrillation. Observational studies have also confirmed the feasibility of this therapy in clinical practice and support its early application in patients with nonventricular fibrillation cardiac arrest and in post-resuscitation circulatory shock. In patients with acute MI, available clinical evidence does not yet support HT as the standard of care, because no study to date has shown a clear net benefit in such a cohort. After a brief review of the mechanisms of action for HT, we provide a review of the clinical evidence, cooling techniques, and potential adverse effects associated with HT in the setting of post-cardiac arrest patient and acute MI. Copyright 2012 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.All authors: Delhaye C, Mahmoudi M, Waksman RDigital Object Identifier: Date added to catalog: 2013-09-17
Holdings
Item type Current library Collection Call number Status Date due Barcode
Journal Article MedStar Authors Catalog Article Available 22240124

Available online from MWHC library: 1995 - present, Available in print through MWHC library:1999-2007

Due to its protective effect on the brain and the myocardium, hypothermia therapy (HT) has been extensively studied in cardiac arrest patients with coma as well as in patients presenting with acute myocardial infarction (MI). In the setting of cardiac arrest, randomized studies have shown that HT decreases mortality and improves neurological outcomes. Subsequent guidelines have therefore recommended cooling (32C to 34C) for 12 to 24 h in unconscious adult patients with spontaneous circulation after out-of-hospital cardiac arrest due to ventricular fibrillation. Observational studies have also confirmed the feasibility of this therapy in clinical practice and support its early application in patients with nonventricular fibrillation cardiac arrest and in post-resuscitation circulatory shock. In patients with acute MI, available clinical evidence does not yet support HT as the standard of care, because no study to date has shown a clear net benefit in such a cohort. After a brief review of the mechanisms of action for HT, we provide a review of the clinical evidence, cooling techniques, and potential adverse effects associated with HT in the setting of post-cardiac arrest patient and acute MI. Copyright 2012 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

English

Powered by Koha